|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Y, Han F, Cao LH, Li C, Wang JW, Li
Q, Zheng W, Guo ZX, Li AH and Zhou JH: Dose-response relationship
in cisplatin-treated breast cancer xenografts monitored with
dynamic contrast-enhanced ultrasound. BMC Cancer. 15:1362015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shahmabadi H Ebrahimi, Movahedi F,
Esfahani M Koohi Moftakhari, Alavi SE, Eslamifar A, Anaraki G
Mohammadi and Akbarzadeh A: Efficacy of Cisplatin-loaded polybutyl
cyanoacrylate nanoparticles on the glioblastoma. Tumour Biol.
35:4799–4806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pirker R: Adjuvant chemotherapy in
patients with completely resected non-small cell lung cancer.
Transl Lung Cancer Res. 3:305–310. 2014.PubMed/NCBI
|
|
7
|
Hjelle LV, Gundersen PO, Oldenburg J,
Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Bremnes RM and Haugnes
HS: Long-term platinum retention after platinum-based chemotherapy
in testicular cancer survivors: A 20-year follow-up study.
Anticancer Res. 35:1619–1625. 2015.PubMed/NCBI
|
|
8
|
Woźniak K and Błasiak J: Recognition and
repair of DNA-cisplatin adducts. Acta Biochim Pol. 49:583–596.
2002.PubMed/NCBI
|
|
9
|
Haddox CL, Han G, Anijar L, Binitie O,
Letson GD, Bui MM and Reed DR: Osteosarcoma in pediatric patients
and young adults: A single institution retrospective review of
presentation, therapy and outcome. Sarcoma. 2014:4025092014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jeanes A, Gottardi CJ and Yap AS:
Cadherins and cancer: How does cadherin dysfunction promote tumor
progression? Oncogene. 27:6920–6929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han SP and Yap AS: The cytoskeleton and
classical cadherin adhesions. Subcell Biochem. 60:111–135. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Azmi AS: Unveiling the role of nuclear
transport in epithelial-to-mesenchymal transition. Curr Cancer Drug
Targets. 13:906–914. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patel IS, Madan P, Getsios S, Bertrand MA
and MacCalman CD: Cadherin switching in ovarian cancer progression.
Int J Cancer. 106:172–177. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lim J and Thiery JP:
Epithelial-mesenchymal transitions: Insights from development.
Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu L, Liu S, Guo W, Zhang C, Zhang B, Yan
H and Wu Z: hTERT promoter activity identifies osteosarcoma cells
with increased EMT characteristics. Oncol Lett. 7:239–244.
2014.PubMed/NCBI
|
|
16
|
Livak and Schmittgen, . Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bruheim S, Xi Y, Ju J and Fodstad O: Gene
expression profiles classify human osteosarcoma xenografts
according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Clin Cancer Res. 15:7161–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou F, Liu H, Zhang X, Shen Y, Zheng D,
Zhang A, Lai Y and Li H: Proline-rich protein 11 regulates
epithelial-to-mesenchymal transition to promote breast cancer cell
invasion. Int J Clin Exp Pathol. 7:8692–8699. 2014.PubMed/NCBI
|
|
20
|
Chen CH, Lin DS, Cheng CW, Lin CJ, Lo YK,
Yen CC, Lee AY and Hsiao CD: Cdc6 cooperates with c-Myc to promote
genome instability and epithelial to mesenchymal transition EMT in
zebrafish. Oncotarget. 5:6300–6311. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grelet S, Andries V, Polette M, Gilles C,
Staes K, Martin AP, Kileztky C, Terryn C, Dalstein V, Cheng CW, et
al: The human NANOS3 gene contributes to lung tumour invasion by
inducing epithelial-mesenchymal transition. J Pathol. 237:25–37.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: Implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim YS, Yi BR, Kim NH and Choi KC: Role of
the epithelial-mesenchymal transition and its effects on embryonic
stem cells. Exp Mol Med. 46:e1082014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaufhold S and Bonavida B: Central role of
Snail1 in the regulation of EMT and resistance in cancer: A target
for therapeutic intervention. J Exp Clin Cancer Res. 33:622014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hsu DS, Lan HY, Huang CH, Tai SK, Chang
SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY and Yang MH:
Regulation of excision repair cross-complementation group 1 by
Snail contributes to cisplatin resistance in head and neck cancer.
Clin Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang W, Feng M, Zheng G, Chen Y, Wang X,
Pen B, Yin J, Yu Y and He Z: Chemoresistance to 5-fluorouracil
induces epithelial-mesenchymal transition via up-regulation of
Snail in MCF7 human breast cancer cells. Biochem Biophys Res
Commun. 417:679–685. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kudo-Saito C, Shirako H, Takeuchi T and
Kawakami Y: Cancer metastasis is accelerated through
immunosuppression during Snail-induced EMT of cancer cells. Cancer
Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: Mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moon JH, Yun W, Kim J, Hyeon S, Kang PJ,
Park G, Kim A, Oh S, Whang KY, Kim DW, et al: Reprogramming of
mouse fibroblasts into induced pluripotent stem cells with Nanog.
Biochem Biophys Res Commun. 431:444–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang H, Zhang G, Zhang H, Zhang F, Zhou B,
Ning F, Wang HS, Cai SH and Du J: Acquisition of
epithelial-mesenchymal transition phenotype and cancer stem
cell-like properties in cisplatin-resistant lung cancer cells
through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol.
723:156–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vega MI, Baritaki S, Huerta-Yepez S,
Martinez-Paniagua MA and Bonavida B: A potential mechanism of
rituximab-induced inhibition of tumor growth through its
sensitization to tumor necrosis factor-related apoptosis-inducing
ligand-expressing host cytotoxic cells. Leuk Lymphoma. 52:108–121.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baritaki S, Yeung K, Palladino M, Berenson
J and Bonavida B: Pivotal roles of snail inhibition and RKIP
induction by the proteasome inhibitor NPI-0052 in tumor cell
chemoimmunosensitization. Cancer Res. 69:8376–8385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shah P, Gau Y and Sabnis G: Histone
deacetylase inhibitor entinostat reverses epithelial to mesenchymal
transition of breast cancer cells by reversing the repression of
E-cadherin. Breast Cancer Res Treat. 143:99–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miller CR, Oliver KE and Farley JH: MEK1/2
inhibitors in the treatment of gynecologic malignancies. Gynecol
Oncol. 133:128–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S,
Malaponte G, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade
inhibitors: How mutations can result in therapy resistance and how
to overcome resistance. Oncotarget. 3:1068–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bruheim S, Xi Y, Ju J and Fodstad O: Gene
expression profiles classify human osteosarcoma xenografts
according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Clin Cancer Res. 15:7161–7169. 2009. View Article : Google Scholar : PubMed/NCBI
|
